Therefore, SMARCA2 is an attractive target to inhibit in SMARCA4-mutant cancers, utilising the enhanced reliance of tumour cells on BRM to completely prevent activity of the SWI/SNF chromatin remodeling complex and inhibit cancer cell growth [92]. Here, SMARCA1 is linked to neoplasm.